The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outcomes after CAR-T therapy in patients with multiple myeloma and EMD or PMD
Darren Pan, MD, Icahn School of Medicine at Mount Sinai, New York, NY, discusses a study which investigated the outcomes of patients with relapsed/refractory (R/R) multiple myeloma treated with CAR-T cells who have extramedullary disease (EMD) and paramedullary disease (PMD). Results demonstrated that the presence of EMD but not PMD was associated with significantly worse progression-free survival (PFS) and overall survival (OS) following CAR-T therapy. Dr Pan also discusses patient characteristics at relapse, and emphasizes the importance of exploring novel treatment approaches for patients with EMD. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
